



# ***Alpa Laboratories Ltd.***

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

27<sup>th</sup> May, 2019

To,  
Listing Department,  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001

To,  
Listing Department,  
National Stock Exchange of India Limited.  
'Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference: Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir/ Madam,

This is with reference to our letter dated 13<sup>th</sup> May, 2019 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 2.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Audited Standalone & Consolidated Financial Results of the Company along with Statutory Auditor Report for quarter & year ended on 31<sup>st</sup> March, 2019.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED

*Megha Neema*

Megha Neema  
Company Secretary





Financial Results for Quarter ended 31st March 2019

(Rs. in lacs except EPS)

Particulars	Standalone Results					Consolidated Results	
	Quarter Ended			Year Ended		Year Ended	
	Mar-19	Dec-18	Mar-18	Mar-19	Mar-18	Mar-19	Mar-18
	Unaudited			Audited		Audited	
<b>I. Income</b>							
a) Revenue from operations	1,909.42	2,596.05	1,790.78	7,798.80	6,226.82	7,798.80	6,284.68
b) Other Income	238.05	61.55	47.78	506.52	478.32	529.88	463.50
<b>1. Total income from operations (net) (a+b)</b>	<b>2,147.47</b>	<b>2,657.60</b>	<b>1,838.56</b>	<b>8,305.32</b>	<b>6,705.14</b>	<b>8,328.68</b>	<b>6,748.18</b>
<b>2. Expenses</b>							
a) Cost of materials consumed	1,130.96	1,483.61	991.46	4,645.84	3,311.16	4,645.84	3,311.16
b) Purchases of stock-in-trade	26.26	20.23	64.89	84.66	226.66	84.66	283.51
c) Changes in inventories of fin. goods, stock-in-pro. & stock-	171.56	108.11	59.24	152.61	31.07	152.61	31.07
d) Employee benefits expense	382.55	284.90	287.17	1,204.10	1,025.56	1,204.10	1,025.56
e) Finance costs	6.90	10.38	15.05	56.87	107.15	56.87	107.15
f) Depreciation and amortization expense	24.31	29.31	32.39	109.57	112.89	311.82	315.15
g) Other expenses							
Manufacturing & Operating	111.43	112.32	85.59	425.85	357.32	425.85	357.32
( Stores and spares consumed, power & fuel,							
Others	391.58	312.71	403.63	1,185.37	880.21	1,193.08	855.05
<b>Total expenses</b>	<b>2,245.55</b>	<b>2,361.57</b>	<b>1,939.42</b>	<b>7,864.87</b>	<b>6,052.02</b>	<b>8,074.83</b>	<b>6,285.97</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>(98.08)</b>	<b>296.03</b>	<b>(100.86)</b>	<b>440.45</b>	<b>653.12</b>	<b>253.85</b>	<b>462.21</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>(98.08)</b>	<b>296.03</b>	<b>(100.86)</b>	<b>440.45</b>	<b>653.12</b>	<b>253.85</b>	<b>462.21</b>
<b>6. Tax (Expenses)/ Benefit</b>							
Current tax	125.00	-	210.00	125.00	210.00	125.00	210.00
Deffered Tax	59.02	-	(10.49)	59.02	(10.49)	59.02	(10.49)
Tax Related to Earlier Years	(18.72)	2.01	(21.07)	(16.71)	(21.07)	(9.56)	(16.16)
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>(263.38)</b>	<b>294.02</b>	<b>(279.30)</b>	<b>273.14</b>	<b>474.68</b>	<b>79.39</b>	<b>278.86</b>
<b>8. Other Comprehensive Income</b>							
(i) (a) Items that will not be reclassified to profit or loss	6.73	-	-	6.60	-	6.60	-
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	6.73	-	-	6.60	-	6.60	-
<b>9. Total comprehensive income for the period (16+17)</b>	<b>(270.11)</b>	<b>294.02</b>	<b>(279.30)</b>	<b>266.54</b>	<b>474.68</b>	<b>72.79</b>	<b>278.86</b>
<b>10. Paid-up equity share capital (Face Value `10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity ( excluding revaluation reserve)</b>				<b>8,486.87</b>	<b>8,223.49</b>		<b>7,654.18</b>
<b>12. Debenture Redemption Reserve</b>							
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>(1.28)</b>	<b>1.40</b>	<b>(1.33)</b>	<b>1.27</b>	<b>2.26</b>	<b>0.35</b>	<b>1.33</b>



Mahendras

**Annexure IX Statement of Assets and Liabilities**

Particulars	Standalone		Consolidated	
	Mar-19	Mar-18	Mar-19	Mar-18
	Audited	Audited	Audited	Audited
<b>ASSETS</b>				
<i>Non-current Assets</i>				
(a) Property, plant and equipment	576.13	602.58	576.13	602.58
(b) Capital work-in-progress	11.78	-	11.78	-
(c) Investment properties	-	-	-	-
(d) Goodwill	-	-	202.25	404.50
(e) Investments in subsidiaries, associates and joint venture	1083.85	1,078.61	-	-
(f) Financial assets				
(i) Investments	1840.81	1,291.54	1,840.81	1,291.54
(g) Deferred tax assets (Net)	17.10	76.13	17.10	76.13
<i>Current Assets</i>				
(a) Inventories	1403.87	1,372.30	1,403.87	1,372.30
(b) Financial Assets				
(i) Investments	2996.10	1,770.79	2,996.10	1,770.79
(ii) Trade Receivables	2980.94	2,544.16	2,999.80	2,602.02
(iii) Cash and cash equivalents	13.48	13.50	14.91	19.03
(iv) Bank Balances other than cash and cash equivalents	75.00	2,115.06	75.00	2,115.06
(v) Loans	471.50	468.73	562.61	706.47
(vi) Other financial assets	228.02	114.34	211.58	114.34
(c) Current Tax Assets (net)	32.00	146.93	32.00	146.93
(d) Other current assets	1129.60	1,058.99	1,154.89	925.38
<b>TOTAL - ASSETS</b>	<b>12860.18</b>	<b>12,653.66</b>	<b>12,098.84</b>	<b>12,147.07</b>
<b>EQUITY AND LIABILITIES</b>				
<i>Equity</i>				
(a) Equity Share Capital	2104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	8486.87	8,216.88	7,723.64	7,647.57
<i>Liabilities</i>				
<i>Non-current liabilities</i>				
(a) Financial Liabilities				
(i) Borrowings	41.13	61.37	41.13	61.37
<i>Current liabilities</i>				
(a) Financial Liabilities				
(i) Borrowings	105.31	517.80	105.31	517.80
(ii) Trade payables	1318.23	1,268.49	1,318.65	1,325.62
(iii) Other financial liabilities	148.41	135.99	148.41	135.99
(b) Short term provisions	223.81	106.64	223.93	106.87
(c) Current tax Liabilities (Net)	-	-	-	-
(d) Other current liabilities	432.35	242.43	433.70	247.79
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>12860.18</b>	<b>12,653.66</b>	<b>12,098.84</b>	<b>12,147.07</b>

**Notes -**

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules, 2015 and Companies ( Indian Accounting Standards ) Accounting
- The figures for the quarter ended 31.03.2019 and 31.03.2018 represent the balance between the audited figures in respect of the full financial years and those published till the third quarter of the respective financial years.
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- Application for merger of Norfolk Mercantile Private Limited, Wholly owned subsidiary of Alpa laboratories Limited was filed before NCLT, Mumbai by Norfolk Mercantile Private Limited on 7th December, 2017. The same was approved by the Bench vide Order dated 15th December, 2017. Application was also filed by Alpa laboratories Limited before NCLT Ahmedabad on 15th January, 2018. Against the application an order was issued by the Bench on 2nd February, 2018 for approval of the same in EGM by the Shareholders through Special Resolution. The EGM was conducted on 7th of May, 2018 which approved the same. The Scrutinizer report and the Chairman report was filed on 9th May, 2018. Final petition was filed before the Bench on 15th May, 2018. Till the date of Appoval of Auditor's Report on May 27, 2019 the petition of merger is still pending with NCLT Mumbai Bench .





**Independent Auditor's Report on Annual Standalone Financial Results of ALPA Laboratories Limited Pursuant To the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**To the Board of Directors of Alpa Laboratories Limited,**

1. I have audited the accompanying Statement of Standalone Financial Results of **Alpa Laboratories Limited** ("the Company"), for the year ended March 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. These Standalone Financial results are based on the Standalone Financial statements for the year ended 31<sup>st</sup> March, 2019 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies act, 2013, which are the responsibility of the Company's management. My responsibility is to express an opinion on these Standalone Financial Result based on my audit of the Standalone financial statements for the year ended 31<sup>st</sup> March, 2019.
3. I have conducted my audit in accordance with the standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that i comply with ethical requirements and plan and preform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also assessing the accounting principles used and significant estimates made by the management. I believe that my audit provides a reasonable basis for my opinion.
4. In my opinion and to the best of our information and according to the explanations given to me, the statement:
  - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
  - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended March 31, 2019.



# Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

**Anuradha Ratnaparkhi**

M.Com., FCA



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, INDORE (M.P.) 452 016  
T : +91-731-4979244 M : +91 98934-62644  
E-mail associate@caanuradha.co.in

5. The statement includes the results for the quarter ended March 31, 2019 being the balancing figure between audited figures in respects of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review.

For and on behalf of

**ANURADHA RATNAPARKHI & ASSOCIATES**

Chartered Accountants

Firm Registration No.023451C

A handwritten signature in black ink, appearing to read 'Anuradha Ratnaparkhi', written over a horizontal line.

**ANURADHA RATNAPARKHI**

Proprietor

Membership Number: 075412



Date: This 27<sup>th</sup> day of May, 2019


Place: Indore



**Independent Auditor's Report on Consolidated Financial Results of ALPA Laboratories Limited Pursuant To the Regulation 33 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**To the Board of Directors of Alpa Laboratories Limited,**

1. I have audited the accompanying Statement of Consolidated Financial Results of Alpa Laboratories Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as the Group) for the year ended March 31, 2019 ("The Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 read with Regulation 63 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
2. These Consolidated Financial results are based on the Consolidated Financial statements for the year ended 31<sup>st</sup> March, 2019 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies act, 2013, which are the responsibility of the Holding Company's management. My responsibility is to express an opinion on these Consolidated Financial Result based on our audit of the consolidated financial statements for the year ended 31<sup>st</sup> March, 2019.
3. I have conducted our audit in accordance with the standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also assessing the accounting principles used and significant estimates made by management. I believe that our audit provides a reasonable basis for my opinion.
4. In my opinion and to the best of our information and according to the explanations given to me and based on the consideration of the reports of the other auditor on separate financial statements and on other financial information of the subsidiary, the consolidated financial results:
  - a. includes the financial statement for the year ended 31<sup>st</sup> March, 2019 of the following entities:
    - i) Norfolk Mercantile Private Limited
  - b. are presented in accordance with the requirements of Regulation 33 read with Regulation 63 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and
  - c. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, total comprehensive income and other financial information of the Group for the year ended 31<sup>st</sup> March, 2019.



# Anuradha Ratnaparkhi & Associates

CHARTERED ACCOUNTANTS

**Anuradha Ratnaparkhi**

M.Com., FCA



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, INDORE (M.P.) 452 016  
T : +91-731-4979244 M : +91 98934-62644  
E-mail associate@caanuradha.co.in

5. The statement includes the results for the quarter ended March 31, 2019 being the balancing figure between audited figures in respects of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review.

For and on behalf of  
**ANURADHA RATNAPARKHI & ASSOCIATES**  
Chartered Accountants  
Firm Registration No.023451C

A handwritten signature in black ink, appearing to read 'Anuradha Ratnaparkhi', written over a horizontal line.

**ANURADHA RATNAPARKHI**  
Proprietor  
Membership Number: 075412



Date: This 27<sup>th</sup> day of May, 2019  
Place: Indore





# ***Alpa Laboratories Ltd.***

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

Date: -27<sup>th</sup> May,2019

To,  
Listing Department,  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai - 400 001  
BSE Code: 532878

To,  
Listing Department,  
National Stock Exchange of India Limited.  
Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai - 400 051  
NSE Code: ALPA

Dear Sir,

**Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations,2016 and SEBI Circular CIR/CFD/CMD/56/2016.**

## **DECLARATION**

In Compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations,2016 and SEBI Circular CIR/CFD/CMD/56/2016, we hereby declare that statutory auditors of our company, M/s. Anuradha Ratnaparkhi & Associates, Chartered Accountants (FRN No.023451C), have issued Audit Report with unmodified opinion in respect of Standalone and consolidated financial results for the quarter and year ended 31<sup>st</sup> March 2019 of the company.

Kindly take the same on record.

Thanking you,  
Yours Faithfully

**For ALPA LABORATORIES LIMITED**

*Mahendera*

**MS Chawla  
Director**

